{
    "root": "189a64de-02e3-4e54-8325-31d3b00009df",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "DATROWAY",
    "value": "20250521",
    "ingredients": [
        {
            "name": "DATOPOTAMAB DERUXTECAN",
            "code": "GD2OWY1DTK"
        },
        {
            "name": "HISTIDINE",
            "code": "4QD397987E"
        },
        {
            "name": "HISTIDINE MONOHYDROCHLORIDE MONOHYDRATE",
            "code": "X573657P6P"
        },
        {
            "name": "SUCROSE",
            "code": "C151H8M554"
        },
        {
            "name": "POLYSORBATE 80",
            "code": "6OZP39ZG8H"
        }
    ],
    "indications": "DATROWAY is indicated for the treatment of adult patients with unresectable or metastatic, hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative (IHC 0, IHC 1+ or IHC 2+/ISH-) breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.",
    "contraindications": "For intravenous infusion only. Do not administer as an intravenous push or bolus. DO NOT use Sodium Chloride Injection, USP. ( 2.4 ) Premedicate for prevention of infusion reactions and nausea and vomiting. ( 2.2 ) The recommended dosage of DATROWAY is 6 mg/kg given as an intravenous infusion once every 3 weeks (21-day cycle) until disease progression or unacceptable toxicity. ( 2.2 , 2.3 )",
    "warningsAndPrecautions": null,
    "adverseReactions": "None."
}